首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >JNJ-26070109 ((R)4-bromo-N-(1-(2,4-difluoro-phenyl)-ethyl)-2-(quinoxaline-5-sulfonylamino)-ben zamide): a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
【24h】

JNJ-26070109 ((R)4-bromo-N-(1-(2,4-difluoro-phenyl)-ethyl)-2-(quinoxaline-5-sulfonylamino)-ben zamide): a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.

机译:JNJ-26070109((R)4-溴-N-(1-(2,4-二氟-苯基)-乙基)-2-(喹喔啉-5-磺酰氨基)-苯甲酰胺):一种新颖,有效且选择性的胆囊收缩素2受体拮抗剂具有良好的口服生物利用度。

获取原文
获取原文并翻译 | 示例
           

摘要

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-ben zamide] is a representative of a new chemical class of competitive antagonists of cholecystokinin 2 (CCK2) receptors. In this study, the primary in vitro pharmacology of JNJ-26070109 was evaluated along with the pharmacokinetic and pharmacodynamic properties of this compound in rat and canine models of gastric acid secretion. JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 +/- 0.13), rat (pK(I) = 7.99 +/- 0.08), and dog (pK(I) = 7.70 +/- 0.14) CCK2 receptors. The selectivity of JNJ-26070109 at the CCK2 receptor versus the CCK1 receptor was species-dependent, with the greatest degree of selectivity (>1200-fold) measured at the human isoforms of the CCK1 receptor (selectivity at CCK2 versus CCK1 receptors: human, approximately 1222-fold; rat, approximately 324-fold; dog approximately 336-fold). JNJ-26070109 behaved as a surmountable, competitive, antagonist of human CCK2 receptors in a calcium mobilization assay (pK(B) = 8.53 +/- 0.05) and in pentagastrin-stimulated gastric acid secretion in the isolated, lumen-perfused, mouse stomach assay (pK(B) = 8.19 +/- 0.13). The pharmacokinetic profile of this compound was determined in vivo in rats and dogs. JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 +/- 16; %F dog = 92 +/- 12) with half lives of 1.8 +/- 0.3 and 1.2 +/- 0.1 h in rat and dog, respectively. The pharmacodynamic properties of this compound were investigated using two in vivo models. In conscious rat and dog chronic gastric fistula models of pentagastrin-stimulated acid secretion, JNJ-26070109 had oral EC(50) values of 1.5 and 0.26 muM, respectively. Overall, we have demonstrated that JNJ-26070109 is a high-affinity, selective CCK2 receptor antagonist with good pharmacokinetic properties.
机译:JNJ-26070109 [(R)4-溴-N- [1-(2,4-二氟-苯基)-乙基] -2-(喹喔啉-5-磺酰基氨基)-苯甲酰胺]是新化学类别的代表胆囊收缩素2(CCK2)受体竞争性拮抗剂的研究。在这项研究中,评估了JNJ-26070109的主要体外药理学以及该化合物在大鼠和犬胃酸分泌模型中的药代动力学和药效学特性。 JNJ-26070109对人(pK(I)= 7.99 +/- 0.08),大鼠(pK(I)= 7.99 +/- 0.08)和狗(pK(I)= 7.70 +/- 0.14)CCK2表达高亲和力受体。 JNJ-26070109对CCK2受体和CCK1受体的选择性是物种依赖性的,在CCK1受体的人同工型上测得的选择性最高(> 1200倍)(CCK2对CCK1受体的选择性:人,约1222倍;大鼠约324倍;狗约336倍)。 JNJ-26070109在钙动员试验中(pK(B)= 8.53 +/- 0.05)和五肽胃泌素刺激的胃液分泌在孤立的,腔灌注的小鼠胃中可作为人类CCK2受体的一种可克服的竞争性拮抗剂。分析(pK(B)= 8.19 +/- 0.13)。在大鼠和狗体内确定了该化合物的药代动力学特征。 JNJ-26070109具有较高的口服生物利用度(%F大鼠= 73 +/- 16;%F狗= 92 +/- 12),大鼠和小鼠的半衰期分别为1.8 +/- 0.3和1.2 +/- 0.1 h狗。使用两个体内模型研究了该化合物的药效特性。在清醒的大鼠和狗的五肽胃泌素刺激的酸分泌的慢性胃瘘模型中,JNJ-26070109的口服EC(50)值分别为1.5和0.26μM。总体而言,我们已经证明JNJ-26070109是一种具有良好药代动力学特性的高亲和力,选择性CCK2受体拮抗剂。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号